Phase 3 ICARIA-MM trial, showing promising efficacy and safety for isatuximab in combination with pomalidomide and low-dose dexamethasone in relapsed/refractory MM.
Isatuximab, which is a CD38 targeting antibody.
Tradename Sarclisa.
It is different from daratumumab, because it has a different isotope for binding.
As a monotherapy, response rates are comparable to what we see with daratumumab.
IT requires a short infusion time and relatively limited pre‑med.
Because it activates compliment to a lesser degree it has a favorable tolerability profile.
The rates of infusion reactions are quite low.
ICARIA trial revealed the combination with isatuximab combined with pomalidomide, showed an impressive response rate in relapsed/refractory patients.
Isatuximab is given typically weekly for the first month, and then can be converted onto every 2 weeks thereafter.
Pomalidomide which was given 3 weeks on and 1 week off.
Over 90% of the patients were refractory to lenalidomide.
Associated, essentially with a doubling of PFS.
There was 12‑month median PFS for the 3 drugs, and a six‑month PFS for the 2 drugs.
There was effectively a doubling of response rate from around 35%, to approximately 60% to 70% in the 3-drug combination.
Infusion reactions were low in terms of incidents.
Seeing a trend in favor of overall survival advantage to 3 drugs over the 2.
The use of isatuximab early in the relapsed/refractory course conferred trend favoring survival.
Approved with addition of isatuximab to the combination of carfilzomib and dexamethasone to treat adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy,.
The anti-CD38 treatment of choice for patients with relapsed or refractory multiple myeloma.
Phase 3 IKEMA trial showed that the triplet reduced the risk of disease progression or death by 45% vs Kd alone in this patient population.
The median progression-free survival had not yet been reached with the isatuximab combination.
No statistically significant difference in objective response rate was observed with the triplet vs the doublet, at 86.6% vs 82.9%, respectively; complete response rates were 39.7% vs 27.6%, respectively
Most common adverse events; respiratory tract infection, infusion-related reactions, fatigue. hypertension, diarrhea, pneumonia, dyspnea, and cough
Serious AEs in the isatuximab combination: were pneumonia and upper respiratory tract infections.
The addition of Sarclisa to carfilzomib and dexamethasone reduced risk of disease progression or death by 45%.
The study reinforces the potential for isatuximab to become a standard of care in relapsed or refractory multiple myeloma.